why choose us

First received: April 06, 2023

Clinical Trial: TRAQinform Assessment of Immunotherapy Response

Study Status: Completed

Recruit Status: RECRUITING

Condition: Melanoma

Study Type: OBSERVATIONAL


Official Title: Comprehensive Assessment of Cancer Immunotherapy Response; Investigating the Intent to Change Treatment Decisions Based Upon TRAQinform Immuno Technology

Brief Summary: The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study.Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled.Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC).

Read more